J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Notable Analyst Calls This Week: Oracle, Moderna and Costco Among Top Picks
Pfizer's "weight gain drug" has achieved positive experimental results and is expected to fill the current situation of "no available drugs" in the fatal disease course.
① Unlike weight loss drugs, pfizer monoclinal antibody drug ponegromab aims to reduce factors that suppress appetite in the brain; ② In the field of cancer, about 80% of patients are diagnosed with cachexia and are expected to die within a year. ③ So far, the FDA has not approved any drugs for the treatment of cachexia.
Merck Keytruda With Eisai's Lenvima Succeeds in Late-stage Trial for Liver Cancer
Trending Stocks This Week as Market Bounces Back From Selloff
Merck Keytruda Cuts Mortality Risk in Gastric Cancer by 20%